Bicycle Therapeutics plc Variable Lease, Cost
Bicycle Therapeutics plc (BCYC) reported Variable Lease, Cost of $737.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-07-30
- Bicycle Therapeutics plc variable lease, cost for the quarter ending 2026-06-30 was $737.00K, a 5.03% decline year-over-year.
- Bicycle Therapeutics plc variable lease, cost for the quarter ending 2026-03-31 was $853.00K, a 6.89% increase year-over-year.
- Bicycle Therapeutics plc variable lease, cost for the quarter ending 2025-12-31 was $736.00K, a 10.24% decline year-over-year.
- Bicycle Therapeutics plc variable lease, cost for the quarter ending 2025-09-30 was $921.00K, a 21.18% increase year-over-year.
- Bicycle Therapeutics plc variable lease, cost for fiscal 2025 was $3.23M, a 10.50% increase from fiscal 2024.
- Bicycle Therapeutics plc variable lease, cost for fiscal 2024 was $2.92M, a 5.29% increase from fiscal 2023.
- Bicycle Therapeutics plc variable lease, cost for fiscal 2023 was $2.78M, a 69.02% increase from fiscal 2022.
- Bicycle Therapeutics plc variable lease, cost for fiscal 2022 was $1.64M, a 168.46% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $737.00K 10-Q · filed 2026-07-30 | $1.59M 10-Q · filed 2026-07-30 | $2.33M derived: sum of 3 quarters · filed 2026-07-30 | $3.25M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $853.00K 10-Q · filed 2026-04-30 | $1.59M derived: sum of 2 quarters · filed 2026-04-30 | $2.51M derived: sum of 3 quarters · filed 2026-04-30 | $3.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.66M derived: sum of 2 quarters · filed 2026-03-17 | $2.43M derived: sum of 3 quarters · filed 2026-07-30 | $3.23M 10-K · filed 2026-03-17 |
| 2025-09-30 | $921.00K 10-Q · filed 2025-10-30 | $1.70M derived: sum of 2 quarters · filed 2026-07-30 | $2.50M 10-Q · filed 2025-10-30 | $3.31M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $776.00K 10-Q · filed 2026-07-30 | $1.57M 10-Q · filed 2026-07-30 | $2.39M derived: sum of 3 quarters · filed 2026-07-30 | $3.15M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $798.00K 10-Q · filed 2026-04-30 | $1.62M derived: sum of 2 quarters · filed 2026-04-30 | $2.38M derived: sum of 3 quarters · filed 2026-04-30 | $2.94M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.58M derived: sum of 2 quarters · filed 2026-03-17 | $2.14M derived: sum of 3 quarters · filed 2026-03-17 | $2.92M 10-K · filed 2026-03-17 |
| 2024-09-30 | $760.00K 10-Q · filed 2025-10-30 | $1.32M derived: sum of 2 quarters · filed 2025-10-30 | $2.10M 10-Q · filed 2025-10-30 | $2.86M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $563.00K 10-Q · filed 2025-08-08 | $1.34M 10-Q · filed 2025-08-08 | $2.10M derived: sum of 3 quarters · filed 2026-03-17 | $2.67M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $781.00K 10-Q · filed 2025-05-01 | $1.54M derived: sum of 2 quarters · filed 2026-03-17 | $2.11M derived: sum of 3 quarters · filed 2026-03-17 | $2.91M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $760.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.33M derived: sum of 2 quarters · filed 2026-03-17 | $2.13M derived: sum of 3 quarters · filed 2026-03-17 | $2.78M 10-K · filed 2026-03-17 |
| 2023-09-30 | $566.00K 10-Q · filed 2024-10-31 | $1.37M derived: sum of 2 quarters · filed 2024-10-31 | $2.02M 10-Q · filed 2024-10-31 | $2.65M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $803.00K 10-Q · filed 2024-08-06 | $1.45M 10-Q · filed 2024-08-06 | $2.09M derived: sum of 3 quarters · filed 2025-02-25 | $2.50M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $648.00K 10-Q · filed 2024-05-02 | $1.29M derived: sum of 2 quarters · filed 2025-02-25 | $1.70M derived: sum of 3 quarters · filed 2025-02-25 | $2.02M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $638.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.05M derived: sum of 2 quarters · filed 2025-02-25 | $1.38M derived: sum of 3 quarters · filed 2025-02-25 | $1.64M 10-K · filed 2025-02-25 |
| 2022-09-30 | $410.00K 10-Q · filed 2023-11-02 | $738.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.00M 10-Q · filed 2023-11-02 | $1.17M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $328.00K 10-Q · filed 2023-08-03 | $595.00K 10-Q · filed 2023-08-03 | $763.00K derived: sum of 3 quarters · filed 2024-02-20 | $985.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $267.00K 10-Q · filed 2023-05-04 | $435.00K derived: sum of 2 quarters · filed 2024-02-20 | $657.00K derived: sum of 3 quarters · filed 2024-02-20 | $800.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $390.00K derived: sum of 2 quarters · filed 2024-02-20 | $533.00K derived: sum of 3 quarters · filed 2024-02-20 | $612.00K 10-K · filed 2024-02-20 |
| 2021-09-30 | $222.00K 10-Q · filed 2022-11-03 | $365.00K derived: sum of 2 quarters · filed 2022-11-03 | $444.00K 10-Q · filed 2022-11-03 | $651.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $143.00K 10-Q · filed 2022-08-04 | $222.00K 10-Q · filed 2022-08-04 | $429.00K derived: sum of 3 quarters · filed 2023-02-28 | $582.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $80.00K 10-Q · filed 2022-05-05 | $286.00K derived: sum of 2 quarters · filed 2023-02-28 | $439.00K derived: sum of 3 quarters · filed 2023-02-28 | $603.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $359.00K derived: sum of 2 quarters · filed 2023-02-28 | $523.00K derived: sum of 3 quarters · filed 2023-02-28 | $662.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $153.00K 10-Q · filed 2021-11-04 | $317.00K derived: sum of 2 quarters · filed 2021-11-04 | $456.00K 10-Q · filed 2021-11-04 | $564.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $164.00K 10-Q · filed 2021-08-05 | $303.00K 10-Q · filed 2021-08-05 | $411.00K derived: sum of 3 quarters · filed 2022-03-01 | $502.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $139.00K 10-Q · filed 2021-05-06 | $247.00K derived: sum of 2 quarters · filed 2022-03-01 | $338.00K derived: sum of 3 quarters · filed 2022-03-01 | $425.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $108.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $199.00K derived: sum of 2 quarters · filed 2022-03-01 | $286.00K derived: sum of 3 quarters · filed 2022-03-01 | $390.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $91.00K 10-Q · filed 2019-11-07 | $178.00K derived: sum of 2 quarters · filed 2019-11-07 | $282.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $87.00K 10-Q · filed 2019-08-08 | $167.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |